Fundraising Fox
Page Therapeutics
6 employees on LinkedIn · 2 known investors
Find your way into Page Therapeutics
182 people in our graph share verified history with the Page Therapeutics team — schools, employers, funds. One of them is your warm intro.
Mariagiulia Davideunlockedknows Daniele Scarinci · together at Tethis S.p.A (overlapped)
knows the team · via Idorsia Pharmaceuticals Ltd
knows the team · via Tethis S.p.A
×2knows the team · via Page Therapeutics
×4knows the team · via Fastweb
×3knows the team · via Universitätsspital Basel (USB)
PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
Founders & leadership
CR
Christoph RochlitzCo-founder & Chief Medical OfficerRochlitz is co-founder and Chief Medical Officer of PAGE Therapeutics and Professor Emeritus of Medical Oncology at the University of Basel, where he previously led the Oncology department and Cancer Centre. He completed medical training at universities in Heidelberg, Berlin, Montpellier, and Cambridge, followed by oncology residencies in Germany and Switzerland and postdoctoral research at UCSF and Institut Pasteur; his clinical career focused on breast cancer trials until his 2022 retirement.
DS
KV
Katharina VenturiChief Operating OfficerKatharina Venturi brings 14+ years of drug development experience across oncology, immunology, and cardiovascular indications, working with small molecules, therapeutic antibodies, and engineered compounds in both large pharmaceutical companies and startups. She has led project teams through preclinical and early clinical development stages and has expertise in regulatory processes and clinical trial strategy.
Investors · 2
Claris Ventureslisted by Claris VenturesTorino
How we know: Claris Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Page Therapeutics do?
- PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
- Who founded Page Therapeutics?
- Page Therapeutics was founded by Nicola Aceto, Christoph Rochlitz.
- Who are Page Therapeutics's investors?
- Page Therapeutics's investors include Claris Ventures, XGEN Venture.